A Phase 2a Multicenter, Double‐Blind, Placebo‐Controlled, Crossover Trial to Investigate the Efficacy, Safety, and Toleration of CP‐866,087 (a High‐Affinity Mu‐Opioid Receptor Antagonist) in Premenopausal Women Diagnosed with Female Sexual Arous

Discerning the potential benefit of pharmacotherapy in a heterogeneous condition such as FSAD is challenging. Participation in a clinical trial combined with a commitment to actively engage in sexual activity may in itself create an environment that is conducive to symptom improvement. Orri M, Abraham L, and Giraldi A. A phase 2a multicenter, double‐blind, placebo‐controlled, crossover trial to investigate the efficacy, safety, and toleration of CP‐866,087 (a high‐affinity mu‐opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD). J Sex Med 2013;10:2484-2496.